Drugs / Herpes Zoster (HZ) Vaccine
Herpes Zoster (HZ) Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02538341 Comparator | May 2016 → Dec 2019 | Crohn disease, ankylosing spondylitis, psoriasis, psoriatic arthritis | University of Alabama at Birmingham | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Herpes Zoster (HZ) Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02538341 ↗ |
| Known as | Zoster Vaccine Live | “Zostavax (Zoster Vaccine Live)” NCT02538341 ↗ |
| Known as | ZVL | “live attenuated zoster vaccine (ZVL)” PMID 34570596 ↗ Sep 2021 |
| Modality | Vaccine | “a live attenuated vaccine is available” NCT02538341 ↗ |
| Route | Subcutaneous | “It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.” NCT02538341 ↗ |